Grupo Espanol de Tumores Neuroendocrinos
Quick facts
Phase 3 pipeline
- 177Lu-edotreotide · Oncology
177Lu-edotreotide is a radioligand therapeutic that binds to somatostatin receptor 2 (SSTR2) on neuroendocrine tumor cells and delivers targeted radiation to kill them. - Drug: Everolimus · Oncology
Everolimus inhibits mTOR (mammalian target of rapamycin), a key protein kinase that regulates cell growth and proliferation. - STZ-5FU · Oncology
STZ-5FU is a chemotherapeutic agent that works by interfering with DNA synthesis.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Grupo Espanol de Tumores Neuroendocrinos portfolio CI brief
- Grupo Espanol de Tumores Neuroendocrinos pipeline updates RSS
Frequently asked questions about Grupo Espanol de Tumores Neuroendocrinos
What is Grupo Espanol de Tumores Neuroendocrinos's pipeline?
Grupo Espanol de Tumores Neuroendocrinos has 3 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include 177Lu-edotreotide, Drug: Everolimus, STZ-5FU.
Related
- Sector hub: All tracked pharma companies